For some complex metabolic diseases, such as CVD, NAFLD, and T2DM, IPA participates in disease treatment by stimulating corresponding receptors such as PXR or AHR through the specific gut–organ axis. This evidence concerns the gene NR1I2 and metabolic dysfunction-associated steatotic liver disease.